MOZ-IN-3

Overview

MOZ-IN-3 is an orally active KAT6A (MOZ) inhibitor with an IC 50 of 0.03 μM against human targets, and it exhibits high selectivity over other MYST family histone acetyltransferases. MOZ-IN-3 modulates monocyte function, exerts anti-tumor effects, increases the nucleocytoplasmic ratio, and enhances cellular resistance to chemotherapeutic drug-induced cell death. MOZ-IN-3 is applicable to leukemia-related research.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Histone Acetyltransferase

Product Information

• Catalog No.: HY-149470
• CAS No.: 3059058-07-7
• Molecular Formula: C17H13FN2O3S
• Molecular Weight: 344.36
• Purity: 98.75%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 20 mg/mL (58.08 mM); Clear solution
• Availability: In-stock

Source

Original product source